Skip to main content
Toggle Mobile Menu
AIDS Education and Training Centers National Coordinating Resource Center (AETC NCRC)
Supporting HIV Education for Health Care Professionals
Toggle Search Menu
Main navigation
About
About the AETC Program
Contact Us
Subscribe to Mailing List
Training
Clinical Reference Tools
Guidelines
Trainer Resources
Self-Directed Learning
Consultation
Directory
Directory Home
National Centers & Programs
Regional Offices
Special Projects
Partner Training Networks
Resources
Library home
Topic index
Curricula
HIV Care Tools App
Resource Order Form
Calendar
This Month
Awareness Days
Conferences & Events
Webinars
Submit an Event
Breadcrumb
Home
»
Directory
»
National Centers & Programs
»
AETC National Coordinating Resource Center
»
UCSF Center for HIV Information
UCSF Center for HIV Information
University of California, San Francisco
1700 Owens Street, Suite 316
San Francisco
,
CA
94158
United States
UCSF CHI Online
Website
About
Staff
Resources
ShareSpot Blog
Susa Coffey, MD
Co-Investigator, Medical Editor
[email protected]
Nicolé H. Mandel
Website Manager
[email protected]
Jason Boyce
Web Developer
[email protected]
Mark Alan McCormick
Producer
[email protected]
Mary Salome
Production Manager
[email protected]
Resources: 5
Active / Archive
- Any -
Active
Archive
Title
Publish Date
Sort ascending
Review Date
Best Practices for Finding and Crediting Images
03/13/2023
Stock Image Website and Resource List
03/13/2023
HHS Adult ART Guidelines: Treatment-Experienced Patients
06/10/2021
HHS Adult ART Guidelines: Initial Therapy
06/10/2021
HHS Adult ART Guidelines: HIV and ART in Older People
01/31/2020
Articles: 49
Title
Publish date
Review date
Accessibility: The Bigger Picture
06/02/2016
TargetHIV: New Name, New Look
09/12/2018
Tissue Levels of TAF: Too Low for PrEP?
03/17/2016
Switching from TDF/FTC to TAF/FTC
03/18/2016
PrEP: Bone Density Improves after Stopping TDF/FTC
05/04/2016
HIV Meds Update: ART in Acute HIV--Decreasing HIV DNA
09/27/2016
HIV Meds Update: Treatment as Prevention: Suppressive ART, Condomless Sex, and HIV Transmission Risk - also a Word on HPTN 052
09/27/2016
HIV Meds Update - RAPID: Immediate ART Initiation
09/27/2016
HIV Meds Update: PrEP Uptake by Sex, Race, and Age
09/27/2016
CROI 2017: Failure of Dolutegravir Monotherapy
04/17/2017
CROI 2017: Dolutegravir in 2-Drug Simplification Studies
04/17/2017
CROI 2017: Bictegravir and Dolutegravir, Head-to-Head Comparison
04/17/2017
CROI 2017: Doravirine Noninferior to Darunavir + Ritonavir in Initial Treatment
04/17/2017
Bictegravir in Initial Therapy
09/28/2017
Doravirine in Initial Therapy: DRIVE-AHEAD Study
10/03/2017
Undetectable = Untransmittable: Effective HIV Treatment Prevents HIV Transmission
12/19/2017
Ibalizumab Approved for Persons with Multidrug Resistant HIV
04/11/2018
Naltrexone Improves Virologic Suppression
04/11/2018
Darunavir/Cobicistat/FTC/TAF Single-Pill Combination in Treatment-Experienced Patients: EMERALD Study
04/11/2018
Immediate ART Initiation Improves Time to Viral Suppression
04/11/2018
Bictegravir/TAF/FTC in Women
04/11/2018
Bictegravir Approved for Initial ART, in Combination with TAF/FTC
04/11/2018
Possible Safety Issue with Dolutegravir during Pregnancy: Reports of Neural Tube Defects
05/23/2018
Darunavir/Cobicistat/FTC/TAF Coformulation Approved; More Data from EMERALD Switch Study
08/20/2018
Dolutegravir + 3TC in Initial Therapy
08/21/2018
U=U in PARTNER2 Study of MSM
08/21/2018
Doravirine--New NNRTI Approved by FDA
10/10/2018
Rapid ART Start
10/16/2018
FDA Approves 2-Drug Combination of Dolutegravir + Lamivudine
04/19/2019
PrEP: TDF/FTC vs TAF/FTC in MSM
04/25/2019
Long-Acting Injectable ART: Cabotegravir + Rilpivirine
04/25/2019
Safety of Dolutegravir at Conception: Updated Data
08/29/2020
New ARV Approval - Fostemsavir
09/04/2020
Long-acting Injectable PrEP: Cabotegravir
09/20/2020
HIV Meds Updates - TANGO and SALSA Studies: Switch to DTG/3TC from 3-Drug ART
10/18/2021
10/18/2021
HIV Meds Updates - Long-acting Injectable Therapy: Cabotegravir + Rilpivirine
10/18/2021
10/18/2021
HIV Meds Updates: Long-acting Injectable Therapy: Lenacapavir
10/18/2021
10/18/2021
Long-acting Injectable PrEP Approved: Cabotegravir
02/09/2022
Updated CDC PrEP Guidelines
02/09/2022
HIV Meds Update: Anal Dysplasia Treatment Prevents Anal Cancer - The ANCHOR Study
02/20/2023
FDA Approves Lenacapavir, New Long-Acting Injectable ARV
03/24/2023
START-ing TEMPRANO: Early Initiation of Antiretroviral Therapy for HIV
10/01/2015
Efavirenz, Dolutegravir, and Darunavir: Pharmacokinetics during Pregnancy
04/12/2016
Use of Dolutegravir in Dialysis
05/04/2016
On the Way: The First Protease Inhibitor-Based Single-Tablet Regimen
09/28/2017
Rifampin Drug-Drug Interactions with Newer Antiretrovirals (TAF, Bictegravir, Dolutegravir)
04/11/2018
Tenofovir Alafenamide (TAF) and Darunavir/Cobicistat in Pregnant Women
09/25/2018
Updates in Antiretroviral Treatment during Pregnancy: Dolutegravir in Late Pregnancy
09/25/2018
Dolutegravir in Early Pregnancy: Updates on Possible Risk of Neural Tube Defects
09/25/2018